Novartis in-licenses ImmunoGen's armed-antibody tech; Alexion releases new Soliris data;

@FierceBiotech: Shire pays a steep premium to nab ViroPharma in $4.2B deal. More | Follow @FierceBiotech

@JohnCFierce: Just a few weeks ago Zalicus ($ZLCS) did a 6 for one reverse split to get its stock price back into compliance. Oh well. | Follow @JohnCFierce

@DamianFierce: Still-blazing IPO market takes Ultragenyx from "next year" to "right now." News | Follow @DamianFierce

@EmilyMFierce: Japanese Global Health Innovative Technology Fund awards $5.7M in grants for infectious disease vaccine work. Story | Follow @EmilyMFierce

> Novartis ($NVS) has in-licensed ImmunoGen's antibody-drug conjugate technology for its oncology group. Release

> Alexion Pharmaceuticals ($ALXN) presented data from four clinical trials demonstrating the benefit of using Soliris to treat atypical hemolytic uremic syndrome, an ultra-rare disease associated with organ failure and premature death. Release

> Texas-based ZS Pharma, which last year raised a $46 million venture round, says that ZS-003 met its primary endpoint in a Phase III study for hyperkalemia. Release

Medical Device News

@FierceMedDev: Pfizer, marketing partner pay MA fine for ad overstating EpiPen's benefits. More | Follow @FierceMedDev

@MarkHFierce: Novartis is unloading its blood transfusion Dx unit for more than $1.6B PR. Article | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Chinese investors pursue groundbreaking med tech from Canada's MDI. Story | Follow @MichaelGFierce

> Topera rolls out next-gen heart imaging tech in wake of U.S., EU sign-offs. Story

> TB Dx maker Oxford Immunotec prices IPO shares. More

> FDA report: Intuitive's robots beneficial, but training still lacking. News

Pharma News

@FiercePharma:  Best-read special report this weekend: Top 10 Patent Losses for 2014. Report | Follow @FiercePharma

@CarlyHFierce:  Rare-disease co. ViroPharma finally snatched up after lots of speculation--Shire gets it for $4.2B. Release | Follow @CarlyHFierce

> FDA slaps Aegerion for CEO's fast-and-loose interviews with CNBC. Story

> AstraZeneca to build £120 million U.K. plant. News

> Novartis hives off blood diagnostics for $1.7B in first slim-down sale. Article

CRO News

> Cel-Sci demands $50M from inVentiv over alleged trial fraud. More

> Quintiles paid $146.5M for Novella. Article

> Capsugel bets $20M on Bend's commercial manufacturing. Story

> AMRI steers clear of FDA warning letter after years of fixes. Piece

> Covance partners up for biologics safety testing. Story

Biotech IT News

> Scientists increasingly receptive to life science vendors on social media. News

> Open-access genomics database causes hand-wringing in U.K. More

> Catalent creates web-based tool to ease drug delivery tech selection. Story

> BioDatomics pitches open-source, freemium bioinformatics package. Piece

> Advocacy groups crowdsourcing patient views on risk-benefit of drugs. News

Suggested Articles

Biogen stunned the biotech world Tuesday when it said it would file aducanumab for approval. Now that the dust has settled, what are analysts saying?

Biocytogen uses chromosome engineering for the in situ replacement of mouse antibody genes with the human counterparts.

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.